<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040035</url>
  </required_header>
  <id_info>
    <org_study_id>ACT_IKMS_1</org_study_id>
    <nct_id>NCT05040035</nct_id>
  </id_info>
  <brief_title>ACT-Measurement at Different Location During Left Atrial Ablation Procedures</brief_title>
  <acronym>ACT</acronym>
  <official_title>Influence of Localization of ACT-measurement and Influence of LAA on ACT Among Patients Undergoing Left Atrial Ablation Procedure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Internistisches Klinikum Munchen Sud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Internistisches Klinikum Munchen Sud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ablation of atrial fibrillation is standard therapy for symptomatic patients or patients with&#xD;
      severely reduced systolic left ventricular ejection fraction. Complications of the procedure&#xD;
      are ischemic thrombembolic stroke. Therefore periprocedural treatment with heparin is&#xD;
      administered to acchieve a therapeutic anticoagulation. The efficacy of anticoagulation is&#xD;
      measured by active-clotting time (ACT) which is measured with blood drawn mostly from the V.&#xD;
      femoralis.&#xD;
&#xD;
      Despite controlled anticoagulation periprocedural stroke is published with an incidence of up&#xD;
      to 2% and asymptomatic cerebral embolization from 2% to 15%.&#xD;
&#xD;
      The ACT-Trial has two aims:&#xD;
&#xD;
        1. Analysis of the influence of the localization of blood drawing on the measured ACT:&#xD;
           blood from central venous line, from LA and from LAA.&#xD;
&#xD;
        2. Dependency of the ACT measured in the blood of the LAA with regard to anatomic und&#xD;
           functional LAA-measurements.&#xD;
&#xD;
      Patients will be included scheduled for left atrial ablation procedure and will be divided in&#xD;
      two groups: atrial fibrillation at time of procedure and sinus rhythm at time of procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of mean and median values of ACT measurements from LA und LAA and dependency on anatomic and functional LAA parameters among patients in sinus rhythm.</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Active clotting time from left atrium (LA) and left atrial appendage (LAA) measured at the same time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target values of ACT measured in central venous line, LA and LAA among patients with sinus rhythm</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Active clotting time from left atrium (LA) and left atrial appendage (LAA) measured with regard to target ACT over time during ablation procedure among patients with sinus rhythm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target values of ACT measured in central venous line, LA and LAA among patients with atrial fibrillation</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Active clotting time from left atrium (LA) and left atrial appendage (LAA) measured with regard to target ACT over time during ablation procedure among patients with atrial fibrillation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of ACT values over time from samples taken from central venous line, LA and LAA among patients with sinus rhythm</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Active clotting time from left atrium (LA) and left atrial appendage (LAA) measured with regard to time behaviour during ablation procedure among patients with sinus rhythm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of ACT values over time from samples taken from central venous line, LA and LAA among patients with atrial fibrillation</measure>
    <time_frame>During ablation procedure</time_frame>
    <description>Active clotting time from left atrium (LA) and left atrial appendage (LAA) measured with regard to time behaviour during ablation procedure among patients with atrial fibrillation.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ACT measurement</intervention_name>
    <description>Measurement of active clotting time (ACT)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with atrial fibrillation scheduled for left atrial ablation procedure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients aged 18 until 80 years with atrial fibrillation scheduled for left atrial&#xD;
        ablation procedure (according to 20216 ESC Guidelines for the management of atrial&#xD;
        fibrillation&quot; and/or &quot;2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on&#xD;
        catheter and surgical ablation of atrial fibrillation&quot; 3. signed informed consent. 4.&#xD;
        hemoglobin &gt;10 g/dl in Messungen up to 8 weeks before inclusion.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Incompliance or contraindication of oral anticoagulation prior to ablation procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens Jilek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internistisches Klinikum Munchen Sud</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thorsten Lewalter, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Internistisches Klinikum Munchen Sud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clemens Jilek, PD Dr</last_name>
    <phone>+49 89 72400</phone>
    <phone_ext>0</phone_ext>
    <email>research@jilek.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Hollweg</last_name>
    <phone>+49 89 72400</phone>
    <phone_ext>4361</phone_ext>
    <email>anna.hollweg@gmx.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Internistisches Klinikum München Süd</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81379</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens Jilek, MD</last_name>
      <phone>+498972400</phone>
      <email>research@jilek.de</email>
    </contact>
    <contact_backup>
      <last_name>Anna Hollweg</last_name>
      <phone>+498972400</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>ablation</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>ACT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

